ABBVBy Calypso Research7 min read

AbbVie Inc. (ABBV) Q4 2025 Earnings Analysis

Sky High or Sky Falling? AbbVie’s $16.6B Conundrum

Key Takeaways

AbbVie Inc. (ABBV) reported Q4 2025 earnings with revenue of $16.6B, representing a +10.0% year-over-year change. The stock moved -3.8% on earnings day.

The bull case: Bulls see AbbVie as a durable high-growth pharma compounder, with SKYRIZI/RINVOQ continuing to outperform while an increasingly visible neuroscience, oncology, and psychiatry pipeline plus disciplined BD create multiple new multi‑billion‑dollar franchises into the 2030s.

The bear case: Bears worry that intensifying competition in IBD and immunology, policy-driven pricing pressure, aesthetics softness, and execution risk across a complex next‑wave pipeline will erode growth and margin expansion, leaving limited upside once the current flagship assets mature.

Financial Highlights

  • Revenue: $16.6B (+10.0% YoY)
  • Gross Profit: $14.0B (84.0% margin, +13.1% YoY)
  • Operating Income: $5.8B (35.0% margin, +44.8% YoY)
  • Net Income: $1.8B
  • TTM Revenue: $61.2B

Stock Performance

  • Earnings Day Move: -3.8%
  • Year-to-Date: +0.1%
  • 1-Year Return: +12.4%
  • vs. S&P 500 (since earnings): -3.3%
  • vs. Nasdaq (since earnings): +0.1%

View live ABBV data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from AbbVie Inc.'s Q4 2025 earnings call:

Durability and Upside of SKYRIZI/RINVOQ and the Broader Growth Algorithm

Sentiment: Positive

"Obviously, the combined guidance for this year is already $500 million higher than our 2027 estimate, and we do expect both SKYRIZI and RINVOQ to grow robustly into the 2030s… that longer-term growth is not reflected [in Street models]." — Robert Michael
"We have, I'd say, a profound opportunity to lead in neuroscience for the long term… And then when I look at oncology, we have a very compelling pipeline that doesn't get enough attention… So we have many opportunities to deliver upside to street long-term estimates." — Robert Michael

Competitive Dynamics and Sustainability of SKYRIZI Leadership in IBD (vs Tremfya/IL‑23s/Entyvio)

Sentiment: Positive

"We see definitely a bifurcation in where the capture rate is coming. It's quite clear that our new patient starts are very, very stable… 75% overall in IBD in the frontline setting… it's 80% in Crohn's… which gives you a sense the competitor is coming in and capturing in the second line." — Jeffrey Stewart
"We will shortly see a readout over a head-to-head study with Entyvio… with the head-to-head data for SKYRIZI versus Entyvio, we see a significant opportunity to continue the momentum beyond just the IL-23 growth and the competition that we've been talking about." — Jeffrey Stewart

Business Development Strategy and “Next Wave” Pipeline Construction

Sentiment: Positive

"If you look at the last two years, we've invested over $8 billion in external innovation… more than 30 deals… These are opportunities that can drive growth in the next decade and beyond." — Robert Michael
"Sometimes there's a misconception that we're only interested in early stage. We are willing to invest in late-stage assets… we have plenty of firepower to pursue both early and late-stage opportunities. We're not limited to early stage, and we're focused on our core areas, immunology, neuroscience, oncology, and building out obesity." — Robert Michael

Oncology Strategy: ADCs, Novel Combinations, and Portfolio Gaps

Sentiment: Mixed

"We believe that PD-one VEGF is a terrific combo partner… we're gonna see tmAbA readout in head and neck and ovarian… The other key component… is also having the ability to have a biomarker approach… when you have slightly increased expression profiles you see higher efficacy." — Roopal Thakkar
"We think a T cell engager could be a very nice combination with 706, and we have brought one in-house… we're trying to get [969] data to ASCO… taking our bispecific technology… in prostate cancer… which is a very large tumor type and I would say with still substantial unmet need." — Roopal Thakkar

Sentiment: Mixed

"We believe… at peak, we could potentially up to double the inflow of patients that would basically start to move into the toxin market… The real commercial impact goes to your conversion rate… we would anticipate that once patients start on Trenebot… we have a much higher conversion rate than our existing share." — Jeffrey Stewart
"There are some areas where we have had some share loss. I'd say particularly in Brazil… we do have a geographic mix issue… whereas we have much more stable or growing share in China and Asia… the US and China is a vast majority of the aesthetics business for us." — Jeffrey Stewart

Bull Case

Bulls see AbbVie as a durable high-growth pharma compounder, with SKYRIZI/RINVOQ continuing to outperform while an increasingly visible neuroscience, oncology, and psychiatry pipeline plus disciplined BD create multiple new multi‑billion‑dollar franchises into the 2030s.

Bear Case

Bears worry that intensifying competition in IBD and immunology, policy-driven pricing pressure, aesthetics softness, and execution risk across a complex next‑wave pipeline will erode growth and margin expansion, leaving limited upside once the current flagship assets mature.

Looking Ahead

With revenue growing +10.0% year-over-year, the key question is whether AbbVie Inc. can sustain this growth trajectory, particularly around durability and Upside of SKYRIZI/RINVOQ and the Broader Growth Algorithm. With operating margins at 35.0%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was AbbVie Inc.'s revenue in Q4 2025?

AbbVie Inc. reported Q4 2025 revenue of $16.6B, representing a +10.0% year-over-year change.

Did AbbVie Inc. beat earnings expectations in Q4 2025?

The stock declined -3.8% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Bulls see AbbVie as a durable high-growth pharma compounder, with SKYRIZI/RINVOQ continuing to outperform while an increasingly visible neuroscience, oncology, and psychiatry pipeline plus disciplined BD create multiple new multi‑billion‑dollar franchises into the 2030s.

What is the bull case for ABBV stock?

The bull case for ABBV centers on: Bulls see AbbVie as a durable high-growth pharma compounder, with SKYRIZI/RINVOQ continuing to outperform while an increasingly visible neuroscience, oncology, and psychiatry pipeline plus disciplined BD create multiple new multi‑billion‑dollar franchises into the 2030s.

What is the bear case for ABBV stock?

The bear case for ABBV centers on: Bears worry that intensifying competition in IBD and immunology, policy-driven pricing pressure, aesthetics softness, and execution risk across a complex next‑wave pipeline will erode growth and margin expansion, leaving limited upside once the current flagship assets mature.

How has ABBV stock performed since its Q4 2025 earnings?

ABBV moved -3.8% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +3.3% since earnings. Year-to-date, the stock has returned +0.1%.

Browse all 400+ earnings reports →

Learn More

Analyze ABBV in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for AbbVie Inc. and 400+ other stocks, explore the full platform.

Open ABBV on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.